
BioNTech SE
NASDAQ:BNTX

Intrinsic Value
The intrinsic value of one
BNTX
stock under the Base Case scenario is
31.76
USD.
Compared to the current market price of 101.81 USD,
BioNTech SE
is
Overvalued by 69%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
BioNTech SE
Fundamental Analysis


Revenue & Expenses Breakdown
BioNTech SE
Balance Sheet Decomposition
BioNTech SE
Current Assets | 18.8B |
Cash & Short-Term Investments | 16.8B |
Receivables | 1.5B |
Other Current Assets | 496m |
Non-Current Assets | 3.7B |
Long-Term Investments | 1.3B |
PP&E | 1.2B |
Intangibles | 1.2B |
Other Non-Current Assets | 117.8m |
Free Cash Flow Analysis
BioNTech SE
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
BioNTech SE
Revenue
|
2.8B
EUR
|
Cost of Revenue
|
-415.5m
EUR
|
Gross Profit
|
2.3B
EUR
|
Operating Expenses
|
-3.5B
EUR
|
Operating Income
|
-1.2B
EUR
|
Other Expenses
|
493.5m
EUR
|
Net Income
|
-665.3m
EUR
|
BNTX Profitability Score
Profitability Due Diligence
BioNTech SE's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

Score
BioNTech SE's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
BNTX Solvency Score
Solvency Due Diligence
BioNTech SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Score
BioNTech SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNTX Price Targets Summary
BioNTech SE
According to Wall Street analysts, the average 1-year price target for
BNTX
is 139.02 USD
with a low forecast of 100.23 USD and a high forecast of 179.55 USD.
Dividends
Current shareholder yield for BNTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BNTX
stock under the Base Case scenario is
31.76
USD.
Compared to the current market price of 101.81 USD,
BioNTech SE
is
Overvalued by 69%.